Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$316.50 USD

316.50
623,669

+8.57 (2.78%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $316.68 +0.18 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Intuitive Surgical for Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.

Here's Why You Should Invest in Patterson Companies Stock Now

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

    HMS Holdings Acquires Nebraska-Based Intrado's Accent Unit

    by Zacks Equity Research

    The latest deal is likely to boost HMS Holdings' (HMSY) Payment Integrity solutions business.

    Here's Why You Should Hold on to Masimo (MASI) Stock Now

    by Zacks Equity Research

    Masimo (MASI) raises revenue and earnings guidance for 2019.

    Trina Mukherjee headshot

    6 MedTech Stocks That are Set to Beat the Market in 2020

    by Trina Mukherjee

    Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

    Masimo (MASI) Expands Partnership with Texas-Based Drager

    by Zacks Equity Research

    Masimo (MASI) sees a slew of developments in recent times.

    Urmimala Biswas headshot

    Hill-Rom (HRC) Rides on International Growth, New Launches

    by Urmimala Biswas

    Hill-Rom (HRC) launches RetinaVue 700 Imager, EarlySense and WatchCare in 2019.

    LHC Group Expands Partnership With Ochsner Health System

    by Zacks Equity Research

    LHC Group (LHCG) sees major expansion in partnerships of late.

    Here's Why You Should Add DexCom (DXCM) to Your Portfolio

    by Zacks Equity Research

    DexCom (DXCM) raises its 2019 revenue and EPS guidance.

    Here's Why You Should Hold on to Allscripts Stock for Now

    by Zacks Equity Research

    Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

    Here's Why You Should Bet on Integer Holdings Stock Now

    by Zacks Equity Research

    Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

    LHC Group Expands Partnership With Tennessee-Based Medalogix

    by Zacks Equity Research

    Management at LHC Group (LHCG) expects to complete the expansion by the first quarter of 2020.

    Here's Why You Should Invest in Cardinal Health Stock Now

    by Zacks Equity Research

    Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

    NextGen Healthcare Boosts Patient Care With CHC Strategies

    by Zacks Equity Research

    NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.

    LHC Group Set to Gain From Expansion of LifePoint Health JV

    by Zacks Equity Research

    LHC Group (LHCG) expects approximately $5.4 million in annualized revenues from this transaction.

    Here's Why You Should Retain NextGen Healthcare for Now

    by Zacks Equity Research

    NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

    PDCO vs. WST: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    PDCO vs. WST: Which Stock Is the Better Value Option?

    Here's Why You Should Retain Wright Medical Stock For Now

    by Zacks Equity Research

    Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.

    Here's Why You Should Hold on to Ecolab (ECL) Stock for Now

    by Zacks Equity Research

    Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.

    Here's Why You Should Hold on to Cerner (CERN) Stock Now

    by Zacks Equity Research

    Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

    Here's Why You Should Retain Nevro (NVRO) Stock for Now

    by Zacks Equity Research

    Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

    Here's Why You Should Hold On to HMS Holdings (HMSY) Stock

    by Zacks Equity Research

    HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services. However, high debt continues to raise concerns.

    XRAY or WST: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    XRAY vs. WST: Which Stock Is the Better Value Option?

    West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    West Pharmaceutical (WST) delivered earnings and revenue surprises of 11.27% and 0.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?